Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to
evaluate the safety and recommended phase II dose of the combination of irinotecan and
rucaparib.